Stockscreener 앱 받기
0.661
0.75%
0.0049
시간 외 거래:
.68
0.019
+2.87%
전일 마감가:
$0.6561
열려 있는:
$0.672
하루 거래량:
336.71K
Relative Volume:
0.08
시가총액:
$4.14M
수익:
-
순이익/손실:
$-16.89M
주가수익비율:
-0.0316
EPS:
-20.8847
순현금흐름:
$-16.44M
1주 성능:
+11.17%
1개월 성능:
-17.38%
6개월 성능:
-88.82%
1년 성능:
+419.25%
1일 변동 폭
$0.63
$0.68
1주일 범위
$0.60
$0.73
52주 변동 폭
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
명칭
Glucotrack Inc
전화
972 (8) 675-7878
주소
301 RT 17 NORTH, RUTHERFORD
Compare GCTK vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.661 | 4.11M | 0 | -16.89M | -16.44M | -20.88 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Glucotrack Inc 주식(GCTK)의 최신 뉴스
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
Glucotrack CEO explains tech behind long-term CBGM implant - Drug Delivery Business
Glucotrack Inc Highlights Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association 2026 Scientific Sessions - marketscreener.com
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions - The Manila Times
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions - Moomoo
GlucoTrack Inc. (GCTK) Surges 8%: Testing Key Resistance at $0.53PCR Spike - thelegaladvocate.com
GlucoTrack Inc. (GCTK) Rallies 8.23% as Shares Test Key Resistance LevelBlock Trade Flow - thelegaladvocate.com
GlucoTrack Inc. (GCTK) Rebounds Sharply: Bullish Momentum Building Above SupportContinuation Pattern Picks - thelegaladvocate.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk - TipRanks
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies By Investing.com - Investing.com South Africa
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies - Investing.com
Glucotrack Received Notice of Delisting - TradingView
Glucotrack (GCTK) cited for bid price and equity Nasdaq deficiencies - Stock Titan
Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownership - Stock Titan
Glucotrack Reports Q1 2026 Results and Advances IDE Submission for Implantable Glucose Monitor - Minichart
Glucotrack's 3-Year CGM Aims to Revolutionize Diabetes Management - BriefGlance
TradingKey - TradingKey
Glucotrack 1Q Loss/Shr $2.65 >GCTK - Moomoo
Glucotrack Reports Q1 2026 Net Loss of $4.3M, Cash $3.9M, Files IDE for Implantable CBGM - TradingView
Glucotrack, Inc. Q1 2026: Net loss $(4.33M), EPS $(2.65) — 10-Q Summary - TradingView
Glucotrack, Inc. Submits IDE Application to FDA for Implantable Continuous Blood Glucose Monitoring System and Reports Q1 2026 Financial Results - Quiver Quantitative
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Glucotrack (GCTK) posts Q1 loss as cash tightens and Nasdaq flags delisting - Stock Titan
Glucotrack (NASDAQ: GCTK) Q1 2026 results, IDE filing and cash runway - Stock Titan
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire Inc.
GlucoTrack Stock Short Interest Rises to 59.4% - Moomoo
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why - MSN
What you need to know before buying GlucoTrack (GCTK) (+0.76%) 2026-05-08Mid Cap Momentum - newser.com
How GlucoTrack (GCTK) maintains its asset base | GCTK: GlucoTrack Q Results Lack Revenue, EPS DataFinancial Summary - newser.com
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology - The Manila Times
GlucoTrack Files IDE for Implantable Glucose Monitor - TipRanks
IDE filing advances Glucotrack (NASDAQ: GCTK) implantable glucose monitor - Stock Titan
Glucotrack Submits Blood Glucose Monitoring Technology to FDA - Yahoo Finance
Glucotrack Submits IDE Application for U.S. Clinical Study of Its Implantable Continuous Blood Glucose Monitoring System - citybiz
Glucotrack Submits IDE to FDA for Implantable Continuous Blood Glucose Monitoring System - geneonline.com
Glucotrack submits FDA application for implantable glucose monitor - Investing.com
Glucotrack submits FDA application for implantable glucose monitor By Investing.com - Investing.com Canada
GlucoTrack, Inc. announced it has officially submitted an Investigational Device Exemption (IDE) application to US regulators for its innovative implantable continuous glucose monitoring technology. - Bitget
Glucotrack, Inc. Submits Investigational Device Exemption Application to FDA for Continuous Blood Glucose Monitoring Technology - Quiver Quantitative
Implantable diabetes monitor moves toward U.S. trial without a wearable - Stock Titan
Glucotrack Announces IDE Submission for U.S. Clinical Study of Its Novel Implantable Continuous Blood Glucose Monitoring Technology - Moomoo
GCTK Stock Jumps As Implantable CGM Data Impresses - StocksToTrade
GCTK Jumps As GlucoTrack’s Implantable CGM Data Impresses - timothysykes.com
see if this zone is the one. $Glucotrack (GCTK.US)$ - Moomoo
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Needle-free diabetes care: 6 devices that painlessly monitor blood sugar - Labiotech.eu
Glucotrack Inc (GCTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):